• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Patients with type 2 diabetes are at high risk for development of cardiovascular disease,
including myocardial infarction, stroke, heart failure, and cardiovascular death. Multiple large …

The prevalence of obesity has reached pandemic proportions, and now approximately 25%
of adults in Westernized countries have obesity. Recognized as a major health concern …

Abstract The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …

Obesity is a chronic disease with high prevalence and associated comorbidities, making it a
growing global concern. These comorbidities include type 2 diabetes, hypertension …

Reassessing Human Adipose Tissue Adipose tissue can more than double in mass and
then return to baseline. This review discusses the functional roles of human white and brown …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

Background New obesity medications result in large weight losses. However, long-term
adherence in a real-world setting is challenging, and termination of obesity medication …

Obesity is a chronic, progressive and relapsing disease with a rising global prevalence
associated with increased morbidity and mortality and reduced quality of life. Treatment of …

Abstract Purpose of Review This review examines lifestyle modification for obesity
management with the goal of identifying treatment components that could support the use of …